Compare Twist Bioscience Corp (TWST) vs Williams Companies Inc (WMB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Twist Bioscience Corp vs Williams Companies Inc — how do they compare? Twist Bioscience Corp trades at $88.31 (market cap $5.45B), while Williams Companies Inc trades at $73.43 (market cap $90.70B). The key difference: Williams Companies Inc is far larger — about 16.6× Twist Bioscience Corp's market cap, and Williams Companies Inc pays a 2.83% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| TWST | WMB | |
|---|---|---|
Market Cap | $5.45B | $90.70B |
Sector | Health | Energy |
52-Week High | $102.88 | $79.40 |
52-Week Low | $24.16 | $56.51 |
Enterprise Value | $5.37B | $120.08B |
Dividend Yield | — | 2.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TWST trades at $95.86, up 2.14% today, with a bullish technical signal and strong institutional interest. Revenue growth is robust, rising from $204M in 2022 to $377M in 2025, though the company remains unprofitable with a net income margin of -19.85%. Recent news highlights AI-driven collaborations and earnings beats, but cash flow trends show persistent operational losses.
The outlook is mixed; analyst consensus is bullish with a $91.63 price target, but profitability challenges and negative cash flows pose significant risks. Investment opportunity lies in continued revenue expansion and AI partnerships, while execution risks and high valuations require caution.
Williams Companies (WMB) trades at $73.36, showing minimal daily movement with a slight 0.03% decline. The stock demonstrates strong profitability with 23.4% net income margins and 21.95% ROE, though valuation metrics appear elevated with a P/E of 32.53. Recent developments include a $5.34 billion Blackstone-led investment for power innovation projects and potential $5.5 billion Momentum Midstream acquisition, positioning the company for strategic growth in energy infrastructure.
WMB presents a compelling investment case with strong analyst support (79% buy ratings) and $86 consensus price target representing 17% upside. The company's fee-based midstream model provides revenue stability, while recent strategic investments enhance growth prospects. Key risks include commodity price volatility, execution challenges from major acquisitions, and elevated debt levels at 52% of assets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →About Williams Companies Inc
Williams is a midstream energy company that owns and operates the large Transco and Northwest pipeline systems and associated natural gas gathering, processing, and storage assets. In August 2018, the firm acquired the remaining 26% ownership of its limited partner, Williams Partners.
Read more on WMB →
